T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.835 NOK 10.74% Market Closed
Market Cap: 665.8m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

Thor Medical ASA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Thor Medical ASA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
T
Thor Medical ASA
OSE:TRMED
Interest Income Expense
kr1.6m
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
-3%
Hofseth Biocare ASA
OSE:HBC
Interest Income Expense
-kr7.2m
CAGR 3-Years
2%
CAGR 5-Years
-20%
CAGR 10-Years
-10%
B
Bergenbio ASA
OSE:BGBIO
Interest Income Expense
kr9m
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Interest Income Expense
kr8.9m
CAGR 3-Years
143%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Interest Income Expense
kr9.6m
CAGR 3-Years
593%
CAGR 5-Years
199%
CAGR 10-Years
22%
N
Nykode Therapeutics ASA
OSE:NYKD
Interest Income Expense
$11m
CAGR 3-Years
140%
CAGR 5-Years
178%
CAGR 10-Years
N/A
No Stocks Found

Thor Medical ASA
Glance View

Market Cap
665.8m NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

TRMED Intrinsic Value
0.124 NOK
Overvaluation 96%
Intrinsic Value
Price
T

See Also

What is Thor Medical ASA's Interest Income Expense?
Interest Income Expense
1.6m NOK

Based on the financial report for Jun 30, 2024, Thor Medical ASA's Interest Income Expense amounts to 1.6m NOK.

What is Thor Medical ASA's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-3%

Back to Top